Development and validation of an LC-MS/MS method for the novel PROTAC KT-474 in rat and mouse plasma: Application to dose-dependent pharmacokinetics and metabolite identification in mice.
KT-474 is a novel orally bioavailable proteolysis-targeting chimera (PROTAC) that selectively degrades interleukin-1 receptor-associated kinase 4 (IRAK4) and is currently in phase 2 clinical trials for inflammatory diseases. In this study, we developed and validated a sensitive liquid chromatography-tandem mass spectro...